Dyslipidemia treatment strategies in primary and secondary prevention. Dyslipemia Registry of the Spanish Arteriosclerosis Society.

Abstract

INTRODUCTION:

Clinical studies show that patients with high cardiovascular risk are still far from reaching the therapeutic objectives, especially of the levels of LDL cholesterol. If the management of these patients in specialized units differs from other scenarios is known.

PATIENTS AND METHODS:

61 certified Lipid Units were selected in the Registry of Dyslipemias of the Spanish Arteriosclerosis Society for the collection of study data. The study included 3958 subjects >18 years of age who met the criteria for hypercholesterolemia (LDL cholesterol ≥160 mg/dL or non-HDL cholesterol ≥190 mg/dL) without familial hypercholesterolemia. A total 1,665 subjects were studied with a mean follow-up time of 4.2 years.

RESULTS AND CONCLUSIONS:

A total of 42 subjects had a cardiovascular event since their inclusion in the Registry, which represents 0.6%. There were no differences in the treatment used at follow-up, but 50% of the patients did not reach the therapeutic goals at the visit end of follow-up. An increase in the potency of the lipid-lowering treatment was observed, including PCSK9 inhibitors use in 16.7% of subjects with recurrences.

• Authors: Victoria Marco-Benedí, Ana M Bea, Rosa M Sánchez Hernández, Núria Plana, Pedro Valdivielso, Fernando Civeira
• Journal: Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis (Clin Investig Arterioscler) 2022 Nov-Dec Vol. 34 Issue 6 Pg. 303-310 ISSN: 1578-1879 [Electronic] Spain
• Vernacular Title: Estrategias de tratamiento de las dislipemias en prevención primaria y secundaria. Registro de la Sociedad Española de Arteriosclerosis.
• PMID: 35654677 (Publication Type: Journal Article)
• Copyright: Copyright © 2022 Sociedad Española de Arteriosclerosis. Publicado por Elsevier España, S.L.U. All rights reserved.

Chemical References

• Cholesterol, LDL
• PCSK9 protein, human
• Proprotein Convertase 9
• Hydroxymethylglutaryl-CoA Reductase Inhibitors
• Anticholesteremic Agents

Topics

• Humans
• Cholesterol, LDL
• Proprotein Convertase 9
• Secondary Prevention
• Dyslipidemias (complications, drug therapy)
• Registries
• Arteriosclerosis (drug therapy)
• Hydroxymethylglutaryl-CoA Reductase Inhibitors (therapeutic use)
• Anticholesteremic Agents (therapeutic use)